Horm Metab Res 2012; 44(03): 155-156
DOI: 10.1055/s-0031-1301359
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Progress in Primary Aldosteronism 2

M. Reincke
1   Medizinische Klinik Innenstadt, Ludwig-Maximilians-Universität München, München
,
J. W. Funder
2   Prince Henry’s Institute of Medical Research, Monash Medical Centre, Clayton, Victoria, Australia
,
M. C. Zennaro
3   INSERM, UMRS_970, Paris Cardiovascular Research Center, Paris, France
4   University Paris Descartes, Paris, France
5   Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
,
F. Beuschlein
1   Medizinische Klinik Innenstadt, Ludwig-Maximilians-Universität München, München
› Author Affiliations
Further Information

Publication History

Publication Date:
06 March 2012 (online)

Abbreviations

CT: computed tomography
MRI: magnet resonance imaging
PA: primary aldosteronism

 
  • References

  • 1 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Endocrine Society . Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
  • 2 Reincke M, Beuschlein F, Bidlingmaier M, Funder JW, Bornstein SR. Progress in primary aldosteronism. Horm Metab Res 2010; 42: 371-373
  • 3 Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies – a review of the current literature. Horm Metab Res 2012; 44: 157-162
  • 4 Monticone S, Viola A, Tizzani D, Crudo V, Burrello J, Galmozzi M, Veglio F, Mulatero P. Primary aldosteronism: who should be screened?. Horm Metab Res 2012; 44: 163-169
  • 5 Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170-176
  • 6 Salvà M, Cicala MV, Mantero F. Primary aldosteronism: the role of confirmatory tests. Horm Metab Res 2012; 44: 177-180
  • 7 Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res 2012; 44: 181-187
  • 8 Catena C, Colussi G, Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm Metab Res 2012; 44: 188-193
  • 9 Fourkiotis VG, Hanslik G, Hanusch F, Lepenies J, Quinkler M. Aldosterone and the kidney. Horm Metab Res 2012; 44: 194-201
  • 10 Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res 2012; 44: 208-214
  • 11 Saha S, Willenberg HS, Bornstein SR, Graessler J, Kopprasch S. Diabetic lipoproteins and adrenal aldosterone synthesis – a possible pathophysiological link?. Horm Metab Res. 2012 44. 239-244
  • 12 Künzel HE. Psychopathological symptoms in patients with primary hyperaldosteronism – possible pathways. Horm Metab Res 2012; 44: 202-207
  • 13 Steichen O, Zinzindohoué F, Plouin PF, Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res 2012; 44: 221-227
  • 14 Wang T, Rowland JG, Parmar J, Nesterova M, Seki T, Rainey WE. Comparison of aldosterone production among human adrenocortical cell lines. Horm Metab Res 2012; 44: 245-250
  • 15 Verhovez A, Williams TA, Morello F, Monticone S, Brizzi MF, Dentelli P, Fallo F, Fabris B, Amenta F, Gomez-Sanchez C, Veglio F, Mulatero P. Aldosterone does not modify gene expression in human endothelial cells. Horm Metab Res 2012; 44: 234-238
  • 16 Hannemann A, Wallaschofski H, Rettig R, Völzke H, Samietz S, Nauck M, Bidlingmaier M, Friedrich N. Association of IGF-I and the IGF-I/IGFBP-3 ratio with plasma aldosterone levels in the general population. Horm Metab Res 2012; 44: 228-233
  • 17 Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331 (6018) 768-772
  • 18 Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M, Fallo F, Letizia C, Allolio B, Ceolotto G, Cicala MV, Lang K, Lefebvre H, Lenzini L, Maniero C, Monticone S, Perrocheau M, Pilon C, Plouin PF, Rayes N, Seccia TM, Veglio F, Williams TA, Zinnamosca L, Mantero F, Benecke A, Jeunemaitre X, Reincke M, Zennaro MC. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59: 592-588
  • 19 Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S, Penton D, Plouin PF, Warth R, Allolio B, Jeunemaitre X, Veglio F, Reincke M. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012; 59: 235-240
  • 20 Pallauf A, Schirpenbach C, Zwermann O, Fischer E, Morak M, Holinski-Feder E, Hofbauer LC, Beuschlein F, Reincke M. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. Horm Metab Res 2012; 44: 215-220
  • 21 Funder JW. Primary aldosteronism: are we missing the wood for the trees?. Horm Metab Res 2012; 44: 251-253